Cat. No. 3000
No more than 1 g per individual per year to be sold without prior permission from the license holder.
Alternative Names: Gefitinib, ZD 1839
Chemical Name: N-(3-chloro-4-fluoro-phenyl)-7-meth
Biological ActivityOrally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.
Licensing InformationSold for research purposes only under agreement from AstraZeneca
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 (Suppl. 1) 33. PMID: 11129170.
Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053. PMID: 10815932.
McKillop et al (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641. PMID: 15827338.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Iressa, supplier, Orally, active, selective, EGFR, inhibitors, Epidermal, Growth, Factors, Receptors, ErbB, Her, Receptor, Tyrosine, Kinases, RTKs, AstraZeneca, ZD1839
Find multiple products by catalog number
August 22 - 24, 2014